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Abstract 
Incubation of rat adipocytes with wortmannin, a potent and selective phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor, completely blocked 
the antilipolytic action of insulin (ICs0= 100 nM), the insulin-induced activation and phosphorylation f cGMP-inhibited cAMP phosphodiesterase 
(cGI-PDE) as well as the activation of the insulin-stimulated cGI-PDE kinase (ICs0= 10-30 nM). No direct effects of the inhibitor on the insulin- 
stimulated cGI-PDE kinase, the cGI-PDE and the hormone-sensitive lipase were observed. These data suggest that activation of PI 3-kinase upstream 
of the insulin-stimulated cGI-PDE kinase in the antilipolytic nsulin signalchain has an essential role for insulin-induced cGI-PDE activation/ 
phosphorylation a d anti-lipolysis. 
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I. Introduction 
The mechanisms whereby insulin regulates metabolic 
pathways and cell proliferation and are not fully under- 
stood even though substantial progress during recent 
years has been achieved [1-3]. Activation of the intrinsic 
tyrosine kinase of the insulin receptor is a critical event 
that initiates the diverse effects of insulin. The activated 
receptor phosphorylates specific target proteins trigger- 
ing a series of events resulting in activation of serine/ 
threonine protein kinases and phosphatases, that alter 
the phosphorylation state/activities of key proteins in- 
volved in the regulation of cell metabolism and prolifer- 
ation. One of the most important metabolic actions of 
insulin is the inhibition of catecholamine-induced lipoly- 
sis in adipose tissue. Activation of the adipocyte cGMP- 
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Abbreviations: PI 3-kinase, phosphatidylinositol 3-kinase; cG1-PDE, 
cGMP-inhibited cAMP phosphodiesterase; cAMP-PK, cAMP-depend- 
ent protein kinase; HSL, hormone-sensitive l pase; cGI-PDE IK, 
insulin-stimulated cGMP-inhibited cAMP phosphodiesterase kinase; 
IRS-1, insulin receptor substrate 1;SH2, src homology-2; PAGE, poly- 
acrylamide gelelectrophoresis; KRH, modified Krebs-Ringer buffer 
with HEPES. 
inhibited cAMP phosphodiesterase (cGI-PDE) by insu- 
lin (reviewed in [4]) is believed to be the major mecha- 
nism whereby insulin reduces cellular cAMP leading to 
inactivation of cAMP-dependent protein kinase (cAMP- 
PK), net dephosphorylation f hormone- sensitive lipase 
(HSL) and antilipolysis [5-8]. This activation of cGI- 
PDE is the result of serine phosphorylation [9,10]. A 
more than additive activation and phosphorylation of 
cGI-PDE is seen in response to insulin in the presence 
of catecholamines, i.e. the conditions during which insu- 
lin normally exerts its antilipolytic effect [10,11]. The 
insulin-induced phosphorylation/activation of the cGI- 
PDE is catalyzed by an insulin-stimulated cGI-PDE 
serine kinase (cGI-PDE IK) [12-14]. The identity of this 
protein kinase and the mechanism of its regulation by 
insulin are still unknown. 
Phosphatidylinositol 3-kinase (PI 3-kinase) has been 
suggested to be important in mediating metabolic effects 
of insulin [15] and other non-mitogenic and mitogenic 
stimuli that act through tyrosine kinases [16]. Wortman- 
nin, a potent and selective PI 3-kinase inhibitor [15,17], 
has recently been reported to block the antilipolytic ac- 
tion of insulin and the insulin-stimulated hexose uptake 
in adipocytes [15]. PI 3-kinase, a dual specificity [18] 
lipid- and protein serine kinase, consists of a 110 kDa 
catalytic subunit and an 85-kDa regulatory subunit 
which contains src homology-2 (SH2) domains [19-22]. 
Activation of PI 3-kinase by insulin seems to involve 
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insulin receptor substrate 1 (IRS-1) (reviewed in [23,24]). 
The activated insulin receptor tyrosine kinase phospho- 
rylates IRS-1 on a number of tyrosines in YXXM/ 
YMXM motifs [25,26]. The SH2 domains of the p85 
regulatory subunit of PI 3-kinase are believed to bind to 
phosphorylated YXXM/YMXM motifs on IRS-1 
[25,26]. This insulin-induced association of PI 3-kinase 
with tyrosine phosphorylated IRS-1 increases the kinase 
activity of the 110-kDa catalytic subunit owards PI and/ 
or its phosphorylated derivatives PI(4)P and PI(4,5)P2 
[27,28]. The PI 3-kinase also acts as a serine protein 
kinase by phosphorylating the p85 subunit causing a 
feed-back auto-inhibition [18]. No other exogenous pro- 
tein substrate has been identified. 
The observation that wortmannin blocked the antil- 
ipolytic effect of insulin [15] prompted us to evaluate the 
effect of this PI 3-kinase inhibitor on several inks be- 
lieved to be important in the antilipolytic signalling chain 
activated by insulin. In this report we demonstrate hat 
wortmannin i hibited the insulin-induced activation of 
cGI-PDE IK as well as the activation/phosphorylation 
of cGI-PDE in isolated adipocytes. 
2. Materials and methods 
2.1. Preparation and fractionation of adipocytes 
Adipocytes were prepared according to [30] with modifications [31] 
from 36- to 38-day-old male Sprague-Dawley rats (B&K Universal, 
Stockholm) and resuspended in Krebs-Ringer medium, pH 7.4, con- 
taining 25 mM HEPES, 200 nM adenosine, 119 mM NaCI, 4.95 mM 
KCI, 2.54 mM CaCI2, 1.19 mM KH2PO4, 1.19 mM MgSO4, 2 mM 
glucose and 3.5% bovine serum albumin (KRH). Adipocytes (1.5 2 ml 
of an 8-10% cell suspension) were incubated with wortmannin (0-100 
nM) (Sigma, St. Louis, USA) for 10 min and then with hormones as 
indicated. The cells were quickly washed once and homogenized at 
21°C (10 strokes) in 0.8 ml of 50 mM N-tris(hydroxymethyl)-methyl-2- 
aminoethanesulfonic acid (TES), pH 7.5, containing 40 mM p-nitro- 
phenyl-phosphate, 0.2mM EGTA, 2 mM EDTA, 250 mM sucrose, 1 
mM dithioerythriol, 0.1 mM vanadate and 10 jtg/ml each of antipain, 
leupeptin and pepstatin A, immediately cooled to 4°C and centrifuged 
(50.000 x g, 60 min, 4°C). The crude membrane fraction containing 
cGI-PDE [32] was either resuspended in 50 mM Tris buffer, pH 7.5, 
containing 5 mM MgCI2, 1 mM EDTA, 3 mM benzamidine and 10 
/.tg/ml each of antipain, leupeptin and pepstain A or solubilized in the 
same buffer with 1% Ct3E12 (non-ionic alkyl polyoxyethylene glycol 
detergent from Berol Kemi AB, Stenungsund, Sweden) as described 
[32]. Solubilized cG1-PDE from control cells was used as substrate for 
detection of cGI-PDE IK activity. The fat free cytosolic fraction con- 
taining cGI-PDE IK activity was assayed as described below. 
2.2. Isolation of cGI-PDE from 32p_labelled adipocytes 
Adipocytes (10% cell suspension in KRH containing 300 jtM 
KH2PO4) were labelled with 32p (1 mCi/ml) (Amersham, Little Chal- 
font, UK) for 2 h. Wortmannin (0-1000 nM) was added to the incuba- 
tions (1.5 ml of a 10% cells suspension) 10 min prior to stimulation by 
1 nM insulin. After 10 min with insulin, the cells were washed twice with 
50 mM Tris, pH 7.4, containing 250 mM sucrose, 1 mM EDTA and 
10/lg/ml each of antipain, leupeptin and pepstain A and homogenized. 
cGI-PDE was immunoisolated from the solubilized crude membrane 
fraction [9,10]. Antiserum raised against a peptide (corresponding to
amino acid 423-440 based on the deduced sequence of the recently 
cloned rat adipose tissue cGI-PDE [33,34]) was used to immunoprecip- 
itate the cGI-PDE. [32p]cGI-PDE was visualized after SDS-PAGE [35] 
by digital imaging of 32p (Fujix BAS 2000). 
2.3. Detection of insulin-stimulated cGI-PDE kinase activity 
Aliquots (70/ll) from fat free cytosolic fractions from control and 
wortmannin/insulin treated adipocytes were incubated with solubilized 
cGI-PDE (30 HI) and a phosphorylation buffer (25/tl) containing 200 
/IM [32p]ATP (10,000-50,000 cpm/pmol), 50 mM MgSO4, 5 mM 
dithioerythritol, 250 mM sucrose and 25 /tM cAMP PK inhibitor 
(Sigma, St. Louis, USA) for 10 min at 30°C. Reactions were terminated 
by the addition of 1 ml of 10 mM Tris, pH 7.5, containing 250 mM 
sucrose, 10 mM NaF, 2 mM sodium-pyrophosphate, 1 mM EDTA, 0.1 
mM EGTA and 10/.tg/ml each of antipain, leupeptin and pepstatin A. 
cGI-PDE was isolated and analyzed as described above. 
2.4. Lipolysis 
Adipocytes, (2% cell suspension) were incubated with wortmannin 
or vehicle (DMSO) in KRH for 10 min. Samples (1 ml) were added to 
vials containing either buffer, 100 nM noradrenaline alone or together 
with 1 nM insulin. Glycerol released to the medium during 30 min was 
then determined [36]. 
2.5. Assay of cGI-PDE and HSL activities 
Crude membrane fractions were assayed for cAMP-PDE activity [37] 
for 8 min at 30°C in a total volume of 0.3 ml containing 50 mM HEPES, 
pH 7.5, 0.1 mM EDTA, 8.3 mM MgClz, 0.5 HM [3H]cAMP (200-500 
cpm/pmol) (New England Nuclear, Dreieich, Germany). Under these 
conditions cGI-PDE represented > 90% of total cAMP-PDE activity in 
the membrane fraction [9,32]. HSL was assayed as described [38]. 
3. Results and discussion 
To evaluate the effects of PI 3-kinase inhibition on the 
regulatory mechanisms of lipolysis, isolated adipocytes 
were incubated with wortmannin (0-1000 nM) for 10 
min and the effects of insulin on cGI-PDE IK activity, 
cGI-PDE phosphorylation/activity and antilipolysis 
were determined. As expected 1nM insulin almost com- 
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Fig. 1. Effect of wortmannin on the antilipolytic action of insulin. 
Adipocytes were incubated for 10 min with vehicle (DMSO) or wort- 
mannin at the indicated concentrations before the addition of 100 nM 
noradrenaline alone ([3) or together with 1 nM insulin (e) or no 
hormone addition (o). Lipolysis was measured as glycerol released to 
the medium during 30 min. Each point represents mean val- 
ues + S.E.M. (n = 3). Basal lipolysis was 82 + 15 nmol glycerol/ml 
packed cell volume (PCV)/min and lipolysis stimulated by 100 nM 
noradrenaline was 815 + 47 nmol glycerol/ml PCV/min. 
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Fig. 2. Effect of wortmannin on the insulin-stimulated phosphorylation 
and activation of cGI-PDE. (A) 32P-labelled a ipocytes were incubated 
for 10 min with vehicle (DMSO) or wortmannin at the indicated con- 
centrations before addition of 1 nM insulin, cGI-PDE was immuno- 
isolated, subjected to SDS-PAGE and [32P]cGI-PDE visualized by dig- 
ital imaging of 32p. The same result was obtained in 4 experiments (B). 
In parallel, using unlabelled adipocytes from the same cell preparation, 
the effect of 100 nM wortmannin on activation of cGI-PDE by 1 nM 
insulin was measured in the membrane fraction. Results are expressed 
as% of basal (mean + S.E.M., n -- 3). Basal cGI-PDE activity was 200 
pmol/min/ml PCV. 
pletely inhibited l ipolysis st imulated by 100 nM noradre-  
nal ine (Fig. 1). Wortmannin  completely blocked this an- 
t i l ipolytic effect with an ICs0 = 100 nM, confirming and 
extending a recent report  [15]. Wortmannin  did not effect 
noradrenal ine-st imulated or basal  l ipolysis, indicating 
that adenylate cyclase-induced increase in cAMP, cAMP 
PK-  and HSL activities per se were not affected. In an 
in vitro assay, wortmannin  did not inhibit HSL  activity 
(data not shown). 
Wortmannin  completely blocked (IC50=10 nM) the 
five-fold increase in the phosphory lat ion of the cGI -PDE 
(Fig. 2A) as well as the act ivat ion of  the enzyme (Fig. 2B) 
induced by insulin st imulation. Wortmannin  added to 
the in vitro assay had no effect on cG I -PDE activity 
(data not shown). 
Insul in-st imulated kinases that activate cG I -PDE in 
vitro (cG I -PDE IK)  have been detected in adipocytes 
and in liver after insulin administrat ion to non-diabet ic 
rats [13,14]. A human platelet cG I -PDE IK  that phos- 
phorylates and activates cG I -PDE in vitro has been sug- 
gested to be regulated by serine/threonine phosphory la-  
t ion in response to insulin [12]. As shown in Fig. 3, 
incubat ion of  adipocytes with insulin resulted in a time- 
dependent activation of  cG I -PDE IK  measured as its 
abil ity to phosphory late cG I -PDE in vitro. Act ivat ion of  
this kinase correlated with activation of  cG I -PDE in 
adipocytes (Fig. 3). Hal f -maximal  activation of  cGI -  
PDE IK  was obtained with 1 pM insulin (data not 
shown), in the same range as that causing cGI -PDE 
act ivat ion/phosphorylat ion [9]. Incubat ion of  adipocytes 
with wortmannin  inhibited insul in- induced act ivat ion of  
cG I -PDE IK  with an IC50 value of  about  30 nM (Fig. 4). 
The 46-kDa 32p-labelled phosphoprote in  also observed 
in Fig. 4 is l ikely to be a proteolyt ic  fragment of  the 
cG I -PDE [9] consistent with the inhibit ion of  its phos- 
phory lat ion by wortmannin  with the same IC50. Addi t ion 
of  wortmannin  to cytosolic fractions from insulin-stimu- 
lated cells containing activated cGI -PDE IK  did not in- 
hibit phosphory lat ion of  cG I -PDE,  indicating that PI 
3-kinase is not a cG I -PDE IK.  
Wortmannin  at nanomolar  concentrat ions inhibits PI 
3-kinase as a result of  direct associat ion with the 110 kDa 
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Fig. 3. Time course of insulin stimulation ofcGI-PDE IK and cGI-PDE 
activities in adipocytes. Adipocytes were incubated without or with 1 
nM insulin for the times indicated. Cytosolic fractions were obtained 
and assayed for cGI-PDE IK activity (o), i.e. extent phosphorylation 
of exogenous added cGI-PDE (see section 2). Crude membrane frac- 
tions were obtained and assayed for cGI-PDE activity (<3). The results 
are in each case expressed as% of maximal activity (mean +_ S.E.M., 
n = 3). In the absence of insulin, the cGI-PDE activity was 200 pmol/ 
min/ml PCV. 
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Fig. 4. Effect of wortmannin on insulin stimulation of cGI-PDE IK 
activity in adipocytes. Adipocytes were incubated for 10 min with vehi- 
cle (DMSO) or wortmannin at the indicated concentrations before the 
addition of 1 nM insulin. Cytosolic fractions were prepared and assayed 
for cGI-PDE IK activity, i.e. extent phosphorylation f exogenous 
added cGI-PDE (see section 2). [32p]cGI-PDE was visualized by digital 
imaging of 3~p. The same result was obtained in 3 experiments. 
catalyt ic subunit  [39]. Other kinases such as myosin light 
chain kinase [40] and phosphat idyl inos i to l  4-kinase [15] 
have been reported to be inhibited by wortmannin  at at 
least 100 fold higher concentrat ions than those used in 
the present investigation. Wortmannin  has been reported 
not to inhibit cyclic nucleotide protein kinases, ca lmod-  
ul in-dependent protein kinase II, protein kinase C [40] 
nor  insul in-st imulated tyrosine autophosphory lat ion  f  
the insulin receptor f l -subunit [15]. We have therefore 
assumed that our  results reflect an inhibit ion of  the PI 
3-kinase with wortmannin.  
In conclusion, our  data confirm that wortmannin,  a 
selective PI 3-kinase inhibitor, acts as an inhibitor of  the 
anti l ipolyt ic effect of  insulin [15]. In addit ion we show 
that this inhibit ion blocks the insul in- induced act ivat ion 
of  cytosol ic cG I -PDE IK  and phosphorylat ion/act iva-  
t ion o f  cG I -PDE.  The activities of  these two enzymes 
were not inhibited by wortmannin  in in vitro assays. 
Taken together these results strongly indicate that PI 
3-kinase is involved in mediat ing the anti l ipolytic effect 
at a step(s) upstream of  the activation of  cytosol ic cGI -  
PDE IK.  The identity of  the cG I -PDE IK  and the mech- 
anism whereby PI 3-kinase activates cG I -PDE IK  is 
presently investigated in our laborator ies.  
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